Skip to main content
. Author manuscript; available in PMC: 2022 May 9.
Published in final edited form as: Neurobiol Dis. 2018 Jun 23;126:47–61. doi: 10.1016/j.nbd.2018.05.011

Figure 7. Roscovitine or MK-2206 applied after OGD did not promote axon function recovery.

Figure 7.

Roscovitine (5 μM) applied after OGD did not promote CAP area recovery (Roscovitine, Green; A and B). MK-2206 (5 μM) applied after OGD did not promote CAP area recovery (MK-2206, Salmon; C and D). NS, p > 0.05, unpaired Student’s two-tailed t-test.